Navigation Links
Phase III trial of dapivirine ring begins in Africa: New HIV prevention approach for women
Date:7/24/2012

WASHINGTON, D.C., July 24, 2012 A large clinical trial testing the long-term safety and effectiveness of a new approach for preventing HIV in women a vaginal ring used once a month is now underway in Africa, researchers announced today at the XIX International AIDS Conference (AIDS 2012).

ASPIRE A Study to Prevent Infection with a Ring for Extended Use is a Phase III trial evaluating a vaginal ring that contains dapivirine, a potent antiretroviral (ARV) drug originally developed to treat HIV. The ring slowly releases dapivirine to cells inside the vagina throughout the one-month period that it's worn, potentially giving women discreet, long-acting protection against HIV transmitted through sex.

Nearly 3,500 women in Africa will take part in ASPIRE, which is being led by the Microbicide Trials Network (MTN) and funded by the National Institute of Allergy and Infectious Diseases and the National Institute of Mental Health, which are part of the U.S. National Institutes of Health. The Makerere University-Johns Hopkins University Research HIV Clinical Trial Unit in Kampala, Uganda this week began screening women interested in joining the study. A second site, the Emavundleni Research Center at the Desmond Tutu HIV Foundation, University of Cape Town, South Africa, should be ready to screen potential participants next week. The MTN hopes to conduct ASPIRE at a total of 17 sites in Malawi, Uganda, South Africa, Zambia and Zimbabwe.

A second trial, The Ring Study, is being conducted in parallel with ASPIRE. The Ring Study is being led by the International Partnership for Microbicides (IPM), which developed the dapivirine ring, and will involve about 1,650 women. IPM has already enrolled more nearly 400 participants at trial sites in South Africa since the study launched in April. The Ring Study will also be conducted in Rwanda and is expected to start there in August.

The two sister studies are the first effectiveness trials of
'/>"/>

Contact: Lisa Rossi
rossil@upmc.edu
412-916-3315
Microbicide Trials Network
Source:Eurekalert

Page: 1 2 3 4

Related medicine news :

1. ALS patients differ on treatment choices in later phases of disease
2. Reach2HD, a Phase II study in Huntingtons disease, launched
3. Analysis of KRYSTEXXA phase III data demonstrates improved health-related quality of life and physical function in refractory chronic gout patients
4. Brain Tumor Vaccine Shows Promise in Early Trial
5. URMC clinical trial tests new regimen for hypertension
6. Analysis Finds Clinical Trials Often Small, of Poor Quality
7. US spends far more for health care than 12 industrialized nations, but quality varies
8. New Weight-Loss Drug Shows Promise in Trial
9. Palpitations are predictive of future atrial fibrillation
10. Trial Set to See if Drug Can Prevent Alzheimers
11. Experts call for clinical trials to test non-skeletal benefits of vitamin D
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/1/2015)... , ... September 01, 2015 , ... ... members of the American Society for Dermatologic Surgery, according to a new survey ... ASDS Consumer Survey on Cosmetic Dermatologic Procedures – which reflects views on cosmetic ...
(Date:9/1/2015)... ... 01, 2015 , ... Virginia entrepreneur Marcella Ellis, CEO and ... her firm’s success in the hair care and distribution industry through her combination ... will be providing “Look and learn” live demonstrations, as well as promoting her ...
(Date:9/1/2015)... ... , ... The Jerry Segal Classic to benefit the patients of Magee Rehabilitation ... in Lafayette Hill, PA. Over the past 26 years, the Classic, organized by the ... designed to support patients and their families during their time at Magee Rehabilitation Hospital. ...
(Date:9/1/2015)... , ... September 01, 2015 , ... ... the release of version 5.2 of the FirstSpirit Content Management System with new ... With the new version of FirstSpirit, companies will be well on their way ...
(Date:9/1/2015)... , ... September 01, 2015 , ... The FSH ... incurable disease, facioscapulohumeral muscular dystrophy (FSHD), will be the beneficiary of a collection of ... mission – to raise awareness of the FSH Society and further FSHD research. ...
Breaking Medicine News(10 mins):Health News:Survey: Consumers Prefer ASDS Members 2Health News:Survey: Consumers Prefer ASDS Members 3Health News:Beauty Entrepreneur creates hair extension smart machine and mobile app inspired by UBER technology 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 2Health News:The 26th Jerry Segal Classic Returns to Benefit Patients of Magee Rehabilitation Hospital 3Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 2Health News:e-Spirit boosts Corporate Content Cloud initiative with release of FirstSpirit 5.2 3Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 2Health News:FSH Society Beneficiary of Variety of Fall Fundraising Events 3
... The Simmons firm, a leading national law firm in the ... second Miles for Meso 5K run/walk on Sunday, October 11, ... at www.milesformeso.org . , The Simmons ... 26 in Alton, Ill. Nearly 500 runners and walkers registered, ...
... ... the return of PRE-PEN® penicillin allergy skin testing products to the market. PRE-PEN® received ... with AllerQuest to market and distribute PRE-PEN®. , ... Round Rock, TX (PRWEB) September 30, 2009 -- ALK-Abelló, ...
... play a role, expert contends, , WEDNESDAY, Sept. 30 (HealthDay ... of surgery, not just the rate of those complications, determines ... , The study, which included more than 84,000 people who ... difference in surgical deaths between hospitals with the lowest rate ...
... , CARLSBAD, Calif., Sept. 30 Jenny Craig, Inc., one ... actress and comedian Nicole Sullivan as the newest Jenny Craig ... gave birth to her second child in August 2009, is ... 35 pounds. , (Photo: http://www.newscom.com/cgi-bin/prnh/20090930/NY84610 ...
... 30 Healthcare Realty Trust Incorporated (NYSE: HR ) ... credit facility, which replaces the previous $400 million facility. ... 2012. The facility is priced at 2.80% over LIBOR, ... terms and conditions customary for loans of this nature. ...
... among those with OCD or Tourette syndrome ... have suggested that strep throat may cause or trigger ... has found no evidence of a link. , ... much rarer neuropsychiatric disorders," Dr. Anette Schrag of the ...
Cached Medicine News:Health News:Simmons Law Firm Presents Second 'Miles for Meso' Walk/Run Fundraiser for Mesothelioma Research 2Health News:FDA Approves PRE-PEN Penicillin Allergy Test 2Health News:Surgical Deaths Linked to Handling of Complications 2Health News:Surgical Deaths Linked to Handling of Complications 3Health News:Nicole Sullivan Joins Jenny Craig to Reclaim Her Pre-Baby Body 2Health News:Healthcare Realty Trust Announces New $550 Million Unsecured Revolving Credit Facility 2Health News:Study Debunks Link Between Strep and Brain Disorders 2
(Date:9/1/2015)... --NOWDiagnostics Inc., based in Springdale, Ark. , ... Canada , a move that brings the company ... have greater access to information concerning their health. ... blood-based rapid tests that allow health care providers to ... ailments and diseases. ZBx Corporation, a Toronto ...
(Date:9/1/2015)... , Sept. 1, 2015  Dr. Cindy ... Labs , the cannabis testing subsidiary of DigiPath, Inc. ... Group about the lack of consistency in today,s ... online resource for medical cannabis information, she explained that ... because their lack of uniform requirements makes standardization impossible. ...
(Date:9/1/2015)... 1, 2015   Alpha Imaging LLC , a leading distributor ... announced today that they have been awarded exclusive rights to ... in Michigan.   The new territory supplements Alpha Imaging,s existing Shimadzu sales ... Ohio , Indiana , ... , West Virginia , Delaware ...
Breaking Medicine Technology:NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 2NOWDiagnostics Inc. Acquires Canada's ZBx Corporation 3DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 2DigiPath Labs CSO Dr. Cindy Orser Calls for Uniform Standards for Cannabis Safety Testing 3Alpha Imaging Expands Shimadzu Territory 2
... Medical Systems (NYSE: VAR ) today announced that ... N.A. to repurchase $250 million of its common stock under ... revolving credit facility with Bank of America, N.A. to increase ... Under the accelerated repurchase agreement, Varian will pay $250 ...
... Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced ... trial evaluating the safety and pharmacokinetics of dabigatran ... valves.(1) The 12-week study will compare three doses ... 300mg bid) to warfarin in patients with both ...
Cached Medicine Technology:Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 2Varian Medical Systems Announces $250 Million Accelerated Stock Repurchase; Increases Its Revolving Credit Facility 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 2Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 3Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 4Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 5Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 6Boehringer Ingelheim to Launch RE-ALIGN™ Trial to Evaluate Dabigatran Etexilate in Patients with Mechanical Heart Valves 7
... a whole blood hematology control manufactured specifically ... 120, and the Coulter AcT5diff instruments. The ... white cell differential, positioning the populations within ... systems. The product offers 105-day closed-vial stability ...
... assayed hematology control, offers complete assay values ... with the Coulter GENS, STKS, MAXM and ... stability, 105-day closed-vial stability and is available ... 4.0ml pierceable cap vial is compatible with ...
Abiomed introduces its new intra-aortic balloon (IAB); an easy-to-insert, minimally invasive technology designed to enhance blood flow to the heart and other organs for patients with diminished heart...
Diagnosoft HARP is designed for rapid analysis of tagged cardiac MR images using the HARP technology, which is packaged into an intuitive, easy-to-use graphic user interface....
Medicine Products: